Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Breast Neoplasms 1334Neoplasms 1111Carcinoma, Non-Small-Cell Lung 923Prostatic Neoplasms 755Colorectal Neoplasms 653Lung Neoplasms 626Neoplasm Metastasis 476Multiple Myeloma 449Leukemia, Myeloid, Acute 441Pancreatic Neoplasms 394Ovarian Neoplasms 390Melanoma 350Carcinoma, Hepatocellular 311Brain Neoplasms 293Recurrence 289Squamous Cell Carcinoma of Head and Neck 287Glioblastoma 263Head and Neck Neoplasms 256Stomach Neoplasms 255Precursor Cell Lymphoblastic Leukemia-Lymphoma 242Carcinoma, Renal Cell 241Lymphoma 237Triple Negative Breast Neoplasms 234Endometrial Neoplasms 223Hematologic Neoplasms 220Uterine Cervical Neoplasms 217Urinary Bladder Neoplasms 213Glioma 208Lymphoma, Non-Hodgkin 206Sarcoma 204

Interventions

ravulizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Atypical Hemolytic Uremic Syndrome × 90 days × Clear all
NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔